SCHEMBL4810705

SCHEMBL4810705

COc1cc2c(cc1OCOCC[Si](C)(C)C)CCC2=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.38
MEN1 O00255 1/20 0.38
CYP3A4 P08684 2/20 0.38
GPR84 Q9NQS5 2/20 0.37
ACHE P22303 1/20 0.37
CHRNA7 P36544 1/20 0.37
PDE4A P27815 1/20 0.37
KDM4E B2RXH2 5/20 0.37
ALDH1A1 P00352 4/20 0.37
GAA P10253 2/20 0.37
MAPT P10636 1/20 0.37
MAOA P21397 1/20 0.37
ABCB1 P08183 1/20 0.36
HSD17B10 Q99714 3/20 0.36
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.36
TUBB4A P04350 1/20 0.36
TUBB P07437 1/20 0.36
TUBA3C P0DPH7 1/20 0.36
TUBA1B P68363 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4815593 0.85 HSD17B1 (0.35)
SCHEMBL29420327 0.78 KMT2A (0.56) KMT2AMEN1CYP3A4ACHEKDM4E
SCHEMBL29420326 0.78 KMT2A (0.56) KMT2AMEN1CYP3A4ACHEKDM4E
SCHEMBL354177 0.78 KMT2A (0.56) KMT2AMEN1CYP3A4ACHEKDM4E
SCHEMBL4808764 0.77 KDM4E (0.33) KMT2AMEN1CYP3A4KDM4EALDH1A1
SCHEMBL3970718 0.77 KMT2A (0.44) KMT2AMEN1CYP3A4GPR84ACHE
SCHEMBL17043164 0.77 ACHE (0.42) KMT2AACHEPDE4AKDM4EALDH1A1
SCHEMBL9741669 0.76 TUBB4A (0.38) KMT2AMEN1ACHEKDM4EALDH1A1
SCHEMBL9322233 0.76 KMT2A (0.47) KMT2AMEN1CYP3A4ACHEKDM4E
SCHEMBL3081962 0.75 KMT2A (0.42) KMT2AMEN1CYP3A4GPR84ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7320986-B2 Fused tri and tetra-cyclic pyrazole kinase inhibitors ABBOTT LABORTORIES (US) 2008-01-22 US disclosed
US-20040259904-A1 Fused tri and tetra-cyclic pyrazole kinase inhibitors ABBVIE INC. 2004-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259904-A1 Fused tri and tetra-cyclic pyrazole kinase inhibitors TK1, MAP3K19, MAP3K20 KMT2A 3073/4885MEN1 1900/4885CYP3A4 3543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.